Story thread · 2 reports / 2 sources
Brian Wolpin celebrates FDA approval of daraxonrasib in pancreatic cancer as the future of the field
cancerletter.com · 12d
How the coverage leans
Across 2 sources · syndicated copies counted once
On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. This episode is available on Spotify, Apple Podcasts, and Youtube. The approval was […] The post Brian Wolpin celebrates FDA approval of daraxonrasib in pancreatic cancer as the future of the field appeared first on The Cancer Letter .
First report: Business Watch: Solstice, Element cancel deal; FDA approves daraxonrasib for pancreatic cancer — cen.acs.org, 13d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.